Drug Information

Drug General Information
Drug ID
D0E0ZR
Former ID
DAP000307
Drug Name
Rimonabant
Synonyms
Acomplia; Rimoslim; Riobant; Slimona; A 281; SR 141716; SR141716; SR141716A; [3H]SR141716A; Acomplia (TN); Bethin (TN); Monaslim (TN); Remonabent (TN); Rimonabant [USAN:INN]; Rimoslim (TN); Riobant (TN); Riomont (TN); SR-141716; SR-141716A; SR141,716A; Slimona (TN); Zimulti (TN); Rimonabant (JAN/USAN/INN); 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide; 5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
Drug Type
Small molecular drug
Indication Obesity [ICD9: 278; ICD10:E66] Withdrawn from market [537145], [542474]
Therapeutic Class
Antiobesity Agents
Company
Sanofi-Aventis
Structure
Download
2D MOL

3D MOL
Formula
C22H21Cl3N4O
InChI
InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)/i1T3
InChIKey
JZCPYUJPEARBJL-RLXJOQACSA-N
CAS Number
CAS 158681-13-1
PubChem Compound ID
54585418
PubChem Substance ID
131283188, 135651209
SuperDrug ATC ID
A08AX01
Target and Pathway
Target(s) Cannabinoid receptor 1 Target Info Antagonist [536549], [536956], [537149]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
BDNF signaling pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 537145Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32.
Ref 542474(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 745).
Ref 536549Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
Ref 536956End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov. 2008 Dec;7(12):961-2.
Ref 537149Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.